Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: A 4 week randomized multicentre controlled trial

Se Hwa Yoo, Sung Hak Park, Jeong Sup Song, Kyung Ho Kang, Choon Sik Park, Jee Hong Yoo, Byoung Whui Choi, Myung Ho Hahn

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalRespirology
Volume6
Issue number1
DOIs
Publication statusPublished - 2001 May 9

Keywords

  • Leukotriene receptor antagonist
  • Mild-to-moderate asthma
  • Pranlukast
  • Randomized clinical trial

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: A 4 week randomized multicentre controlled trial'. Together they form a unique fingerprint.

Cite this